Blueprint Medicines Outlines Precision Therapy Research Vision, Provides Update on Discovery and Clinical-Stage Portfolio at R&D Day and Reports Third Quarter 2019 Financial Results

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/14/2026

1. ADBE
2. SPCX
3. USO
4. SPY
5. RH
6. NVDA
7. RKLB
8. CRM
9. MSFT
10. CRWV

Go back to Blueprint Medicines Outlines Precision Therapy Research Vision, Provides Update on Discovery and Clinical-Stage Portfolio at R&D Day and Reports Third Quarter 2019 Financial Results

Blueprint Medicines (BPMC) Reports Q3 Loss of $1.93/Share

November 5, 2019 7:28 AM EST

Blueprint Medicines (NASDAQ: BPMC) reported Q3 EPS of ($1.93), versus $1.66 reported last year. Revenue for the quarter came in at $9.14 million, versus $1.1 million reported last year.

For earnings history and earnings-related data on Blueprint Medicines (BPMC) click here.

... More